Pharmacokinetic/pharmacodynamic profile of posaconazole

Clinical Pharmacokinetics

Volumn 49, Issue 6, 2010, Pages 379-396

  Li, Yanjun ^a   Theuretzbacher, Ursula ^b   Clancy, Cornelius J ^c   Nguyen, M Hong ^c   Derendorf, Hartmut ^a  

^a UNIVERSITY OF FLORIDA HEALTH   (United States)

^b Center For Anti Infective Agents Vienna   (Austria)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; ASTEMIZOLE; ATAZANAVIR; CARBAMAZEPINE; CIMETIDINE; CISAPRIDE; CYCLOSPORIN A; CYTOCHROME P450 3A4; DIGOXIN; DOFETILIDE; EFAVIRENZ; FAMOTIDINE; FLUCONAZOLE; HALOFANTRINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IRINOTECAN; ITRACONAZOLE; LOPINAVIR; LORAZEPAM; MIDAZOLAM; NELFINAVIR; PHENYTOIN; PIMOZIDE; POSACONAZOLE; QUINIDINE; RAPAMYCIN; RIFABUTIN; TACROLIMUS; UNINDEXED DRUG; VORICONAZOLE;

AGE; ANTIFUNGAL ACTIVITY; ANTIFUNGAL RESISTANCE; ASPERGILLUS; ASPERGILLUS FLAVUS; ASPERGILLUS FUMIGATUS; ASPERGILLUS TERREUS; BACKACHE; BLASTOMYCES DERMATITIDIS; CANDIDA; CRYPTOCOCCUS NEOFORMANS; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG STRUCTURE; FATIGUE; FEBRILE NEUTROPENIA; FOOD; FOOD DRUG INTERACTION; HEADACHE; HOT FLUSH; HUMAN; HYPERBILIRUBINEMIA; HYPOKALEMIA; IMMUNOCOMPROMISED PATIENT; LIVER DYSFUNCTION; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MYCOSIS; NAUSEA; PETRIELLIDIUM BOYDII; PHARMACODYNAMICS; PRIORITY JOURNAL; PRURITUS; RACE; RASH; REVIEW; SEX; SINGLE DRUG DOSE; SOMNOLENCE; TIME TO MAXIMUM PLASMA CONCENTRATION; ZYGOMYCETES;

ANIMALS; ANTIFUNGAL AGENTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; DRUG INTERACTIONS; DRUG RESISTANCE, FUNGAL; FOOD-DRUG INTERACTIONS; FUNGI; HUMANS; MYCOSES; TRIAZOLES;

EID: 77952529779     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.2165/11319340-000000000-00000     Document Type: Review

References (148)

1. Koltin Y, Hitchcock CA. The search for new triazole antifungal agents. Curr Opin Chem Biol 1997; 1: 176-182
2. Oakley KL, Moore CB, Denning DW. In vitro activity of SCH-56592 and comparison with activities of amphotericin B and itraconazole against Aspergillus spp. Antimicrob Agents Chemother 1997; 41: 1124-1126
3. Keating GM. Posaconazole. Drugs 2005; 65: 1553-67; discussion 1568-1569
4. Sun QN, Fothergill AW, McCarthy DI, et al. In vitro activities of posaco-nazole, itraconazole, voriconazole, amphotericin B, and fluconazole against 37 clinical isolates of zygomycetes. Antimicrob Agents Chemother 2002; 46: 1581-1582
5. Cacciapuoti A, LoebenbergD, Corcoran E, etal. In vitro and in vivo activities of SCH 56592 (posaconazole), a new triazole antifungal agent, against Aspergillus and Candida. Antimicrob Agents Chemother 2000; 44: 2017-2022
6. Manavathu EK, Cutright JL, Loebenberg D, et al. A comparative study of the in vitro susceptibilities of clinical and laboratory-selected resistant isolates of Aspergillus spp. to amphotericin B, itraconazole, voriconazole and posaconazole (SCH 56592). J Antimicrob Chemother 2000; 46: 229-234
7. Groll AH, Walsh TJ. Posaconazole: clinical pharmacology and potential for management of fungal infections. Expert Rev Anti Infect Ther 2005; 3: 467-487
8. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998; 26: 1-10
9. Courtney R, Pai S, Laughlin M, et al. Pharmacokinetics, safety, and toler-ability of oral posaconazole administered in single and multiple doses in healthy adults. Antimicrob Agents Chemother 2003; 47: 2788-2795
10. Theuretzbacher U, IhleF, Derendorf H. Pharmacokinetic/pharmacodynamic profile of voriconazole. Clin Pharmacokinet 2006; 45: 649-663
11. Greer ND. Posaconazole (Noxafil): a new triazole antifungal agent. Proc (Bayl Univ Med Cent) 2007; 20: 188-196
12. Pfizer Inc. Diflucan® (fluconazole): LAB-0099-6.1. New York: Pfizer Inc., 2004 Aug [online]. Available from URL: http://www.fda.gov/ohrms/dockets/ ac/05/briefing/2005-4180b-04-05-Diflucan%20label%2010-04%20Division. pdf [Accessed 2010 Mar 16]
13. Janssen Pharmaceutica Products, LP. Sporanox® (itraconazole) oral sus-pension: hepatotoxicity labeling-62602. Titusville (NJ): Janssen Pharmaceutica Products LP, 2002 Jun
14. European Medicines Agency. Posaconazole SP: European public assess-ment report. Scientific discussion. London: European Medicines Agency, 2006 Dec
15. Courtney R, Radwanski E, Lim J, et al. Pharmacokinetics of posaconazole coadministered with antacid in fasting or nonfasting healthy men. Antimicrob Agents Chemother 2004; 48: 804-808
16. Courtney R, Wexler D, Radwanski E, et al. Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults. Br J Clin Pharmacol 2004; 57: 218-222
17. Torres HA, Hachem RY, Chemaly RF, et al. Posaconazole: a broad-spectrum triazole antifungal. Lancet Infect Dis 2005; 5: 775-785
18. Schering-Plough Inc. Label: Noxafil® (posaconazole) oral suspension. Labeling-31029708. Kenilworth (NJ): Schering-Plough Inc., 2006 Oct
19. Ezzet F, Wexler D, Courtney R, et al. Oral bioavailability of posaconazole in fasted healthy subjects: comparison between three regimens and basis for clinical dosage recommendations. Clin Pharmacokinet 2005; 44: 211-220
20. Andes D,Marchillo K,Conklin R, etal. Pharmacodynamics of anew triazole, posaconazole, in a murine model of disseminated candidiasis. Antimicrob Agents Chemother 2004; 48: 137-142
21. Andes D, Marchillo K, Stamstad T, et al. In vivo pharmacodynamics of a new triazole, ravuconazole, in a murine candidiasis model. Antimicrob Agents Chemother 2003; 47: 1193-1199 (Pubitemid 36368574)
22. Courtney R, Sansone A, Smith W, et al. Posaconazole pharmacokinetics, safety, and tolerability in subjects with varying degrees of chronic renal disease. J Clin Pharmacol 2005; 45: 185-192
23. Krieter P, Flannery B, Musick T, et al. Disposition of posaconazole following single-dose oral administration in healthy subjects. Antimicrob Agents Chemother 2004; 48: 3543-3551
24. Herbrecht R. Voriconazole: therapeutic review of a new azole antifungal. Expert Rev Anti Infect Ther 2004; 2: 485-497
25. Ezzet F, Wexler D, Courtney R, et al. Comparative bioavailability of oral posaconazole (POS) in different dosage regimens: a population pharmacokinetic analysis [abstract]. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; 2003 Sep 14-17; Chicago (IL)
26. Conte Jr JE, Golden JA, Krishna G, et al. Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects. Antimicrob Agents Chemother 2009; 53: 703-707
27. Perfect JR, Cox GM, Dodge RK, et al. In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans. Antimicrob Agents Chemother 1996; 40: 1910-1913
28. Wexler D, Courtney R, Richards W, et al. Effect of posaconazole on cyto-chrome P450 enzymes: a randomized, open-label, two-way crossover study. Eur J Pharm Sci 2004; 21: 645-653
29. Ghosal A, Hapangama N, Yuan Y, et al. Identification of human UDP-glucuronosyltransferase enzyme(s) responsible for the glucuronidation of posaconazole (Noxafil). Drug Metab Dispos 2004; 32: 267-271 (Pubitemid 38176945)
30. Meletiadis J, Chanock S, Walsh TJ. Human pharmacogenomic variations and their implications for antifungal efficacy. Clin Microbiol Rev 2006; 19: 763-787 Posaconazole: SCH 56592.
31. Drugs R D 2003; 4: 258-63
32. Sansone-Parsons A, Krishna G, Simon J, et al. Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers. Antimicrob Agents Chemother 2007; 51: 495-502
33. Krishna G, AbuTarif M, Xuan F, et al. Pharmacokinetics of oral posaco-nazole in neutropenic patients receiving chemotherapy for acute myelogen-ous leukemia or myelodysplastic syndrome. Pharmacotherapy 2008; 28: 1223-1232
34. Cornely OA, Maertens J, Winston D, et al. Pharmacokinetics (PK) of oral posaconazole (POS) in neutropenic patients with acute myelogenous leukemia (AML) [abstract]. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2006 Sep 27-30; San Francisco (CA)
35. Sansone-Parsons A, Krishna G, Calzetta A, et al. Effect of a nutritional supplement on posaconazole pharmacokinetics following oral administration to healthy volunteers. Antimicrob Agents Chemother 2006; 50: 1881-1883
36. Krishna G, Sansone-Parsons A, Martinho M, et al. Posaconazole plasma concentrations in juvenile patients with invasive fungal infection. Anti-microb Agents Chemother 2007; 51: 812-818
37. Hachem RY, Langston AA, Graybill JR, et al. Posaconazole as salvage treatment of invasive fungal infections in patients with underlying renal impairment. J Antimicrob Chemother 2008; 62: 1386-1391
38. Langston A, Ullmann AJ, Cornely OA, et al. Pharmacokinetics (PK) and safety of posaconazole (POS) as prophylaxis for invasive fungal infection in high-risk patients [abstract]. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2006 Sep 27-30; San Francisco (CA)
39. Ullmann AJ, Cornely OA, Burchardt A, et al. Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection. Antimicrob Agents Chemother 2006; 50: 658-666
40. Lewis R, Hogan H, Howell A, et al. Progressive fusariosis: unpredictable posaconazole bioavailability, and feasibility of recombinant interferon-gamma plus granulocyte macrophage-colony stimulating factor for refractory disseminated infection. Leuk Lymphoma 2008; 49: 163-165
41. Nagappan V, Deresinski S. Reviews of anti-infective agents: posaconazole: a broad-spectrum triazole antifungal agent. Clin Infect Dis 2007; 45: 1610-1617
42. Alexander BD, Perfect JR, Daly JS, et al. Posaconazole as salvage therapy in patients with invasive fungal infections after solid organ transplant. Transplantation 2008; 86: 791-796
43. Statkevich P, Courtney RD, Laughlin M, et al. Potential for a drug interaction between posaconazole and phenytoin [abstract]. 41th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2001 Dec 16-19; Chicago (IL)
44. European Medicines Agency. Noxafil: European public assessment report. Scientific discussion. London: European Medicines Agency, 2005 [online]. Available from URL: http://www.ema.europa.eu/humandocs/PDFs/EPAR/noxafil/ 32017905en6.pdf [Accessed 2010 Mar 16]
45. Worth LJ, Blyth CC, Booth DL, et al. Optimizing antifungal drug dosing and monitoring to avoid toxicity and improve outcomes in patients with hae-matological disorders. Intern Med J 2008; 38: 521-537
46. Johns Hopkins POC-IT Center. ABX guide: posaconazole [online]. Available from URL: http://hopkins-abxguide.org/antibiotics/antifungal/posaconazole. html?contentInstanceId=414399 [Accessed 2010 Mar 16]
47. Saad AH, DePestel DD, Carver PL. Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants. Pharmacotherapy 2006; 26: 1730-1744
48. Moton A, Ma L, Krishna G, et al. Effect of oral posaconazole (POS) on the pharmacokinetics (PK) of sirolimus [abstract]. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2007 Oct 25-28; Chicago (IL)
49. European Union's CHMP adopts positive opinion for Noxafil® (posacona-zole) oral suspension for prevention of invasive fungal infections [media release]. 2006 Sep 22 [online]. Available from URL: http://www2. prnewswire. com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/09-22-2006/ 00044 37836&EDATE=[Accessed 2010 Mar 16]
50. SP Europe. Posaconazole: summary of product characteristics [online]. Available from URL: http://www.ema.europa.eu/humandocs/PDFs/EPAR/posaconazoleSP/ H-611-PI-en.pdf [Accessed 2010 Mar 16]
51. Courtney R, Statkavich P, Martinho M, et al. Assessment of the pharm-acokinetic, and pharmacodynamic interaction potential between posaconazole and glipizide in healthy volunteers. 13th European Congress of Clinical Microbiology and Infectious Diseases; 2003 May 10-13; Glasgow
52. Hyland R, Jones BC, Smith DA. Identification of the cytochrome P450 en-zymes involved in the N-oxidation of voriconazole. Drug Metab Dispos 2003; 31: 540-547
53. Tarani L, Costantino F, Notheis G, et al. Long-term posaconazole treatment and follow-up of rhino-orbital-cerebral mucormycosis in a diabetic girl. Pediatr Diabetes 2009; 10: 289-293
54. Snelders E, van der Lee HA, Kuijpers J, et al. Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism. PLoS Med 2008; 5: e219
55. Ruping MJ, Albermann N, Ebinger F, et al. Posaconazole concentrations in the central nervous system. J Antimicrob Chemother 2008; 62: 1468-1470
56. Anstead GM, Corcoran G, Lewis J, et al. Refractory coccidioidomycosis treated with posaconazole. Clin Infect Dis 2005; 40: 1770-1776
57. Greenberg RN, Mullane K, van Burik JA, et al. Posaconazole as salvage therapy for zygomycosis. Antimicrob Agents Chemother 2006; 50: 126-133
58. Raad II, Graybill JR, Bustamante AB, et al. Safety of long-term oral posa-conazole use in the treatment of refractory invasive fungal infections. Clin Infect Dis 2006; 42: 1726-1734
59. Raad II, Hachem RY, Herbrecht R, et al. Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions. Clin Infect Dis 2006; 42: 1398-1403
60. StorzingerD,Lichtenstern C, SwobodaS, etal. Posaconazole in intensive care patients I: invasive fungal infections in surgical intensive care and case presentation. Mycoses 2008; 51 Suppl. 2: 52-57
61. Medical review for NDA 22-1003 NoxafilC3 (posaconazole) [online]. Avail-able from URL: http://www.fda.gov/cder/foi/nda/2006/022003s000-Noxafil- MedR.pdf [Accessed 2009 May 18]
62. Sambatakou H. Posconazole: pharmacology and drug interactions [online]. Available from URL: http://www.aspergillus.org.uk/indexhome. htm?secure/articles/posaconazole/posaconazole.html [Accessed 2010 Mar 16]
63. Vazquez JA, Skiest DJ, Nieto L, et al. A multicenter randomized trial eval-uating posaconazole versus fluconazole for the treatment of oropharyngeal candidiasis in subjects with HIV/AIDS. Clin Infect Dis 2006; 42: 1179-1186
64. Graybill JR, Bocanegra R, Najvar LK, et al. SCH56592 treatment of murine invasive aspergillosis. J Antimicrob Chemother 1998; 42: 539-542
65. Petraitiene R, Petraitis V, Groll AH, et al. Antifungal activity and pharm-acokinetics of posaconazole (SCH 56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: correlation with galacto-mannan antigenemia. Antimicrob Agents Chemother 2001; 45: 857-869
66. Barchiesi F, Schimizzi AM, Caselli F, et al. Activity of the new antifungal triazole, posaconazole, against Cryptococcus neoformans. J Antimicrob Chemother 2001; 48: 769-773 (Pubitemid 33735311)
67. Connolly P, Wheat J, Schnizlein-Bick C, et al. Comparison of a new triazole antifungal agent, Schering 56592, with itraconazole and amphotericin B for treatment of histoplasmosis in immunocompetent mice. Antimicrob Agents Chemother 1999; 43: 322-328
68. Lutz JE, Clemons KV, Aristizabal BH, et al. Activity of the triazole SCH 56592 against disseminated murine coccidioidomycosis. Antimicrob Agents Chemother 1997; 41: 1558-1561
69. Wollina U, Hansel G, Vennewald I, et al. Successful treatment of relapsing disseminated coccidioidomycosis with cutaneous involvement with posaco-nazole. J Dtsch Dermatol Ges 2009; 7: 46-49
70. Lozano-Chiu M, Arikan S, Paetznick VL, et al. Treatment of murine fusariosis with SCH 56592. Antimicrob Agents Chemother 1999; 43: 589-591
71. Brugiere O,Dauriat G, Mal H, et al. Pulmonary mucormycosis (zygomycosis) in a lung transplant recipient: recovery after posaconazole therapy. Transplantation 2005; 80: 1361-1362
72. Chau AS, Chen G, McNicholas PM, et al. Molecular basis for enhanced activity of posaconazole against Absidia corymbifera and Rhizopus oryzae. Antimicrob Agents Chemother 2006; 50: 3917-3919
73. Sabatelli F, Patel R, Mann PA, et al. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob Agents Chemother 2006; 50: 2009-2015
74. Spreghini E, Maida CM, Milici ME, et al. Posaconazole activity against Candida glabrata after exposure to caspofungin or amphotericin B. Anti-microb Agents Chemother 2008; 52: 513-517 (Pubitemid 351170822)
75. Pfaller MA, Diekema DJ, Messer SA, et al. In vitro activities of voriconazole, posaconazole, and four licensed systemic antifungal agents against Candida species infrequently isolated from blood. J Clin Microbiol 2003; 41: 78-83
76. Pfaller MA, Messer SA, Boyken L, et al. In vitro activities of voriconazole, posaconazole, and fluconazole against 4,169 clinical isolates of Candida spp. and Cryptococcus neoformans collected during 2001 and 2002 in the ARTEMIS global antifungal surveillance program. Diagn Microbiol Infect Dis 2004; 48: 201-205
77. Marco F, Pfaller MA, Messer SA, et al. In vitro activity of a new triazole antifungal agent, SCH 56592, against clinical isolates of filamentous fungi. Mycopathologia 1998; 141: 73-77
78. Espinel-Ingroff A. Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J Clin Microbiol 1998; 36: 2950-2956
79. Meletiadis J, Meis JF, Mouton JW, et al. In vitro activities of new and conventional antifungal agents against clinical Scedosporium isolates. Antimicrob Agents Chemother 2002; 46: 62-68
80. Paphitou NI, Ostrosky-Zeichner L, Paetznick VL, et al. In vitro antifungal susceptibilities of Trichosporon species. Antimicrob Agents Chemother 2002; 46: 1144-1146
81. Barchiesi F, Arzeni D, Camiletti V, et al. In vitro activity of posaconazole against clinical isolates of dermatophytes. J Clin Microbiol 2001; 39: 4208-4209
82. Gonzalez GM, Tijerina R, Najvar LK, et al. In vitro and in vivo activities of posaconazole against Coccidioides immitis. Antimicrob Agents Chemother 2002; 46: 1352-1356
83. Espinel-Ingroff A. In vitro antifungal activities of anidulafungin and mica-fungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature. Rev Iberoam Micol 2003; 20: 121-136
84. Paphitou NI, Ostrosky-Zeichner L, Paetznick VL, et al. In vitro activities of investigational triazoles against Fusarium species: effects of inoculum size and incubation time on broth microdilution susceptibility test results. Antimicrob Agents Chemother 2002; 46: 3298-3300
85. Marimon R, Serena C, Gene J, et al. In vitro antifungal susceptibilities of five species of sporothrix. Antimicrob Agents Chemother 2008; 52: 732-734
86. Pfaller MA, Diekema DJ, Sheehan DJ. Interpretive breakpoints for fluco-nazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing. Clin Microbiol Rev 2006; 19: 435-447
87. Sims CR, Paetznick VL, Rodriguez JR, et al. Correlation between micro-dilution, E-test, and disk diffusion methods for antifungal susceptibility testing of posaconazole against Candida spp. J Clin Microbiol 2006; 44: 2105-2108
88. Pfaller MA, Diekema DJ, Rex JH, et al. Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints. J Clin Microbiol 2006; 44: 819-826
89. Rex JH, Pfaller MA. Has antifungal susceptibility testing come of age? Clin Infect Dis 2002; 35: 982-989
90. Seifert H,AurbachU, StefanikD, et al. Invitro activities of isavuconazole and other antifungal agents against Candida bloodstream isolates. Antimicrob Agents Chemother 2007; 51: 1818-1821
91. Lortholary O, Raoux D, Hoinard D. In vitro susceptibility to posaconazole (POS) of 1327 yeast isolates recovered from bloodstream infections in France (2003-2006) using the EUCAST method [abstract]. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2006 Sep 27-30; San Francisco (CA)
92. Lortholary O, Dannaoui E, Raoux D, et al. In vitro susceptibility to posa-conazole of 1,903 yeast isolates recovered in France from 2003 to 2006 and tested by the method of the European Committee on Antimicrobial Susceptibility Testing. Antimicrob Agents Chemother 2007; 51: 3378-3380
93. Wynne SM, Kwon-Chung KJ, Shea YR, et al. Invasive infection with Tri-chosporon inkin in 2 siblings with chronic granulomatous disease. J Allergy Clin Immunol 2004; 114: 1418-1424
94. Messer SA, Jones RN, Fritsche TR. International surveillance of Candida spp. and Aspergillus spp.: report from the SENTRY Antimicrobial Surveillance Program (2003). J Clin Microbiol 2006; 44: 1782-1787
95. Cuenca-Estrella M, Gomez-Lopez A, Mellado E, et al. Head-to-head com-parison of the activities of currently available antifungal agents against 3,378 Spanish clinical isolates of yeasts and filamentous fungi. Antimicrob Agents Chemother 2006; 50: 917-921
96. Pfaller MA, Messer SA, Boyken L, et al. Global trends in the antifungal susceptibility of Cryptococcus neoformans (1990 to 2004). J Clin Microbiol 2005; 43: 2163-2167
97. Gonzalez GM, Fothergill AW, Sutton DA, et al. In vitro activities of new and established triazoles against opportunistic filamentous and dimorphic fungi. Med Mycol 2005; 43: 281-284
98. Wheat LJ, Connolly P, Smedema M, et al. Activity of newer triazoles against Histoplasma capsulatum from patients with AIDS who failed fluconazole. J Antimicrob Chemother 2006; 57: 1235-1239
99. Espinel-IngroffA.Utility of mould susceptibility testing. Curr Opin Infect Dis 2003; 16: 527-532
100. Cuenca-Estrella M, Gomez-Lopez A, Mellado E, et al. In vitro activity of ravuconazole against 923 clinical isolates of nondermatophyte filamentous fungi. Antimicrob Agents Chemother 2005; 49: 5136-5138
101. Pfaller MA, Messer SA, Hollis RJ,et al. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000. Antimicrob Agents Chemother 2002; 46: 1032-1037
102. Diekema DJ, Messer SA, Hollis RJ, et al. Activities of caspofungin, itraco-nazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi. J Clin Microbiol 2003; 41: 3623-3626
103. Warn PA, Sharp A, Denning DW. Invitro activity of a new triazole BAL4815, the active component of BAL8557 (the water-soluble prodrug), against Aspergillus spp. J Antimicrob Chemother 2006; 57: 135-138 (Pubitemid 43057070)
104. Gilgado F, Serena C, Cano J, et al. Antifungal susceptibilities of the species of the Pseudallescheria boydii complex. Antimicrob Agents Chemother 2006; 50: 4211-4213
105. Carrillo AJ, Guarro J. In vitro activities of four novel triazoles against Scedosporium spp. Antimicrob Agents Chemother 2001; 45: 2151-2153
106. Cuenca-Estrella M, Diaz-Guerra TM, Mellado E, et al. Comparative in vitro activity of voriconazole and itraconazole against fluconazole-susceptible and fluconazole-resistant clinical isolates of Candida species from Spain. Eur J Clin Microbiol Infect Dis 1999; 18: 432-435
107. Alastruey-Izquierdo A, Cuenca-Estrella M, Monzon A, et al. Antifungal susceptibility profile of clinical Fusarium spp. isolates identified by molecular methods. J Antimicrob Chemother 2008; 61: 805-809
108. Gupta AK, Kohli Y, Batra R. In vitro activities of posaconazole, ravucona-zole, terbinafine, itraconazole and fluconazole against dermatophyte, yeast and non-dermatophyte species. Med Mycol 2005; 43: 179-185
109. Nucci M, Anaissie E. Fusarium infections in immunocompromised patients. Clin Microbiol Rev 2007; 20: 695-704
110. Manavathu EK, Ramesh MS, Baskaran I, et al. A comparative study of the post-antifungal effect (PAFE) of amphotericin B, triazoles and echino-candins on Aspergillus fumigatus and Candida albicans. J Antimicrob Chemother 2004; 53: 386-389
111. Manavathu EK, Cutright JL, Chandrasekar PH. Organism-dependent fun-gicidal activities of azoles. Antimicrob Agents Chemother 1998; 42: 3018-3021
112. Sugar AM, Liu XP. In vitro and in vivo activities of SCH 56592 against Blastomyces dermatitidis. Antimicrob Agents Chemother 1996; 40: 1314-1316
113. Graybill JR, Hernandez S, Bocanegra R, et al. Antifungal therapy of murine Aspergillus terreus infection. Antimicrob Agents Chemother 2004; 48: 3715-3719
114. Gonzalez GM, Tijerina R, Najvar LK, et al. Activity of posaconazole against Pseudallescheria boydii: in vitro and in vivo assays. Antimicrob Agents Chemother 2003; 47: 1436-1438
115. Pfaller MA, Sheehan DJ, Rex JH. Determination of fungicidal activities against yeasts and molds: lessons learned from bactericidal testing and the need for standardization. Clin Microbiol Rev 2004; 17: 268-280
116. Sun QN, Najvar LK, Bocanegra R, et al. In vivo activity of posaconazole against Mucor spp. in an immunosuppressed-mouse model. Antimicrob Agents Chemother 2002; 46: 2310-2312
117. Cacciapuoti A, Halpern J, Mendrick C, et al. Interaction between posaco-nazole and caspofungin in concomitant treatment of mice with systemic Aspergillus infection. Antimicrob Agents Chemother 2006; 50: 2587-2590
118. Najvar LK, Cacciapuoti A, Hernandez S, et al. Activity of posaconazole combined with amphotericin B against Aspergillus flavus infection in mice: comparative studies in two laboratories. Antimicrob Agents Chemother 2004; 48: 758-764
119. Barchiesi F, Spreghini E, Schimizzi AM, et al. Posaconazole and amphote-ricin B combination therapy against Cryptococcus neoformans infection. Antimicrob Agents Chemother 2004; 48: 3312-3316
120. Cacciapuoti A, Gurnani M, Halpern J, et al. Interaction between posacona-zole and amphotericin B in concomitant treatment against Candida albicans in vivo. Antimicrob Agents Chemother 2005; 49: 638-642
121. Perea S, Lopez-Ribot JL, Kirkpatrick WR, et al. Prevalence of molecular mechanisms of resistance to azole antifungal agents in Candida albicans strains displaying high-level fluconazole resistance isolated from human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2001; 45: 2676-2684
122. Li X, Brown N, Chau AS, et al. Changes in susceptibility to posaconazole in clinical isolates of Candida albicans. J Antimicrob Chemother 2004; 53: 74-80
123. Pfaller MA, Messer S, Jones RN. Activity of a new triazole, SCH 56592, compared with those of four other antifungal agents tested against clinical isolates of Candida spp. and Saccharomyces cerevisiae. Antimicrob Agents Chemother 1997; 41: 233-235
124. Pfaller MA, Messer SA, Boyken L, et al. Geographic variation in the sus-ceptibilities of invasive isolates of Candida glabrata to seven systemically active antifungal agents: a global assessment from the ARTEMIS Anti-fungal Surveillance Program conducted in 2001 and 2002. J Clin Microbiol 2004; 42: 3142-3146
125. Magill SS, ShieldsC,Sears CL,etal. Triazole cross-resistance among Candida spp.: case report, occurrence among bloodstream isolates, and implications for antifungal therapy. J Clin Microbiol 2006; 44: 529-535
126. Panackal AA, Gribskov JL, Staab JF, et al. Clinical significance of azole antifungal drug cross-resistance in Candida glabrata. J Clin Microbiol 2006; 44: 1740-1743
127. Bedini A, Venturelli C, Mussini C, et al. Epidemiology of candidaemia and antifungal susceptibility patterns in an Italian tertiary-care hospital. Clin Microbiol Infect 2006; 12: 75-80
128. Guinea J, PelaezT, AlcalaL,et al. Antifungal susceptibility of 596 Aspergillus fumigatus strains isolated from outdoor air, hospital air, and clinical samples: analysis by site of isolation. Antimicrob Agents Chemother 2005; 49: 3495-3497
129. Mellado E, Garcia-Effron G, Alcazar-Fuoli L, et al. A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations. Antimicrob Agents Chemother 2007; 51: 1897-1904
130. Mann PA, Parmegiani RM, Wei SQ, etal. MutationsinAspergillus fumigatus resulting in reduced susceptibility to posaconazole appear to be restricted to a single amino acid in the cytochrome P450 14alpha-demethylase. Anti-microb Agents Chemother 2003; 47: 577-581
131. Mellado E, Alcazar-Fuoli L, Garcia-Effron G, et al. New resistance mech-anisms to azole drugs in Aspergillus fumigatus and emergence of antifungal drugs-resistant A. fumigatus atypical strains. Med Mycol 2006; 44 Suppl.: 367-371
132. Chamilos G, Kontoyiannis DP. Update on antifungal drug resistance mechanisms of Aspergillus fumigatus. Drug Resist Updat 2005; 8: 344-358
133. Howard SJ, Webster I, Moore CB, et al. Multi-azole resistance in Aspergillus fumigatus. Int J Antimicrob Agents 2006; 28: 450-453
134. Espinel-Ingroff A, Fothergill A, Peter J, et al. Testing conditions for de-termination of minimum fungicidal concentrations of new and established antifungal agents for Aspergillus spp.: NCCLS collaborative study. J Clin Microbiol 2002; 40: 3204-3208
135. Andes D, van Ogtrop M. Characterization and quantitation of the pharmacodynamics of fluconazole in a neutropenic murine disseminated candidiasis infection model. Antimicrob Agents Chemother 1999; 43: 2116-2120
136. Louie A, Drusano GL, Banerjee P, et al. Pharmacodynamics of fluconazole in a murine model of systemic candidiasis. Antimicrob Agents Chemother 1998; 42: 1105-1109
137. Lee SC, Fung CP, Huang JS, et al. Clinical correlates of antifungal macro-dilution susceptibilitytest results for non-AIDS patients with severe Candida infections treated with fluconazole. Antimicrob Agents Chemother 2000; 44: 2715-2718
138. Pai MP, Turpin RS, Garey KW. Association of fluconazole area under the concentration-time curve/MIC and dose/MIC ratios with mortality in non-neutropenic patients with candidemia. Antimicrob Agents Chemother 2007; 51: 35-39
139. Clancy CJ, Yu VL, Morris AJ, et al. Fluconazole MIC and the fluconazole dose/MIC ratio correlate with therapeutic response among patients with candidemia. Antimicrob Agents Chemother 2005; 49: 3171-3177
140. Groll AH, Mickiene D, Petraitiene R, et al. Pharmacokinetics and pharmacodynamics of posaconazole (SCH 56592) in a neutropenic animal model of invasive pulmonary aspergillosis [abstract]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 Sep 17-20; Toronto (ON)
141. Andes D, Stamsted T, Conklin R. Pharmacodynamics of amphotericin B in a neutropenic-mouse disseminated-candidiasis model. Antimicrob Agents Chemother 2001; 45: 922-926
142. Andes D, Marchillo K, Lowther J, et al. In vivo pharmacodynamics of HMR 3270,a glucan synthase inhibitor, in a murine candidiasis model. Antimicrob Agents Chemother 2003; 47: 1187-1192
143. Groll AH, Piscitelli SC, Walsh TJ. Antifungal pharmacodynamics: concentration-effect relationships in vitro and in vivo. Pharmacotherapy 2001; 21: 133-48S
144. Theuretzbacher U. Pharmacokinetics/pharmacodynamics of echinocandins. Eur J Clin Microbiol Infect Dis 2004; 23: 805-812
145. Andes D, Marchillo K, Stamstad T, et al. In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model. Antimicrob Agents Chemother 2003; 47: 3165-3169 (Pubitemid 37229574)
146. Deziel MR, Heine H, Louie A, et al. Effective antimicrobial regimens for use in humans for therapy of Bacillus anthracis infections and postexposure prophylaxis. Antimicrob Agents Chemother 2005; 49: 5099-5106
147. Walsh TJ, Raad I, Patterson TF,et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis 2007; 44: 2-12
148. Krishna G, Martinho M, Chandrasekar P, et al. Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease. Pharmacotherapy 2007; 27: 1627-1636